24 May 2023 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis Member news
02 May 2023 Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure Member news
27 Apr 2023 Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis Member news
26 Apr 2023 VIB and Ghent University develop new mRNA vaccines against bacterial infections Member news
20 Mar 2023 Bimekizumab Phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks Member news
14 Mar 2023 Oxurion provides update on recruitment for KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema and announces Board changes Member news
06 Mar 2023 Mithra announces promising topline safety results from Donesta® Phase 3 Study in North America Member news
02 Mar 2023 Mithra announces compelling initial preclinical data in its research collaboration on novel tyrosine kinase inhibitors with BCI Pharma Member news
01 Mar 2023 Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure Member news
09 Feb 2023 Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
